Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions
NCT ID: NCT02311296
Last Updated: 2020-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2020-11-02
2020-11-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A new development in the management of patients requiring mechanical ventilation is the Hi-Lo endotracheal tube. This device has "suction ports" on either side of the tube that allow for the removal of accumulated subglottic secretions.The standard of care is to use this Hi-Lo ET tube and to remove subglottic secretions every 4-6 hours. The Hi-Lo tube is designed to minimize any suction related trauma. Moreover, recent studies of this ET tube have shown that regular suctioning reduces the incidence of VAP. When these "colonized" secretions were treated with antibiotics, it reduced the number of VAP and shortened the time on the breathing machine. The observation that treatment of bacterial colonization of subglottic secretions reduced the time on the breathing machine is potentially very important clinically. In this study, we propose that the development of bacterial colonization directly contributes to respiratory failure and leads to longer times on the ventilator. The primary aim of the study could lead to reduce the time that patients need mechanical ventilation.
Recent studies have identified a group of "protective proteins" called the heat shock proteins (HSP) that appear to protect patients from developing pneumonia. The protective effect of these proteins is even more pronounced in patients that require mechanical ventilation. Under stressed conditions, HSPs are secreted or released into the subglottic secretions and the level of secretion is sufficient appears to prevent bacteria from "colonizing" the upper respiratory tract.
In addition to looking at rates of bacterial colonization of these secretions, a portion of these secretions to measure the amount of HSP and whether reduced secretion leads to prolonged time on the ventilator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients requiring mechanical ventilation for altered mental status, drug overdose or any condition that airway protection from aspiration is clinically warranted
3. Patients requiring mechanical ventilation following Cardiothoracic bypass or valve replacement surgery
4. Patients requiring mechanical ventilation for stroke, intra-cranial bleed, sub-dural hematoma, meningitis or closed head injury
5. Patients requiring mechanical ventilation for following of abdominal surgery in which there were no discernable infiltrates on chest X-ray
6. Patients requiring mechanical ventilation for primary lung disease (COPD, emphysema etc.) if no discernable infiltrates on chest X-ray.
Exclusion Criteria
2\) Patients requiring mechanical ventilation for ARDS, pneumonia or traumatic lung injury.
3\) Patients receiving more than one dose of any antibiotic.
4\) Patients undergoing surgical resection for lung cancer or any other surgery directly involving lung parenchyma
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Tennessee, Chattanooga
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Gunter, MD
Role: PRINCIPAL_INVESTIGATOR
University of Tennessee, Chattanooga
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erlanger Hospital
Chattanooga, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HI-LO Study
Identifier Type: -
Identifier Source: org_study_id